Scientists at the Blanchette Rockefeller Neurosciences Institute are planning to conduct a large-scale study needed to commercialize a skin test that can pinpoint patients with Alzheimer's disease. The diagnostic test works by identifying a class of enzymes, called PKCs, that becomes defective in patients with the condition.

Related Summaries